[Skip to Navigation]
September 2005

Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab Therapy

Arch Dermatol. 2005;141(9):1173-1174. doi:10.1001/archderm.141.9.1173

In the last few years, several clinical trials have demonstrated the efficacy of cetuximab, a chimeric IgG1 monoclonal antibody that binds to the epidermal growth factor receptor, in the treatment of metastatic colorectal cancer.1,2 The most frequent cutaneous adverse effect of cetuximab therapy is an acneiform eruption, observed in approximately 90% of patients within 1 to 3 weeks after therapy initiation.1-5

Add or change institution